Financial News

Medexus to Present at The LD Micro Virtual Invitational XI on June 8th

Products You May Like

TORONTO and CHICAGO and MONTREAL, June 01, 2021 (GLOBE NEWSWIRE) — Medexus Pharmaceuticals Inc. (the “Firm” or “Medexus”) (TSXV: MDP, OTCQX: MEDXF), at present introduced that administration will current on the LD Micro Invitational XI investor convention happening just about June 8-10, 2021.

Ken d’Entremont, Chief Govt Officer of Medexus, and Roland Boivin, Chief Monetary Officer of Medexus, are scheduled to host a digital presentation to buyers in the course of the occasion as follows:

2021 LD Micro Invitational XI
Date: Tuesday, June 8, 2021
Time: 12:30 p.m. EST – Observe 1
Webcast: Sequire | Virtual Events (

For extra data on the LD Micro Invitational XI, or to register for the occasion, please go to

About Medexus Prescription drugs Inc.
Medexus is a number one modern and uncommon illness firm with a robust North American business platform. From a basis of confirmed greatest in school merchandise we’re constructing a extremely differentiated firm with a portfolio of modern and excessive worth orphan and uncommon illness merchandise that may underpin our progress for the following decade. The Firm’s imaginative and prescient is to supply the most effective healthcare merchandise to healthcare professionals and sufferers, by means of our core values of High quality, Innovation, Buyer Service and Teamwork. Medexus Prescription drugs is concentrated on the therapeutic areas of auto-immune illness, hematology, and allergy. The Firm’s main merchandise are: Rasuvo™ and Metoject®, a singular formulation of methotrexate (auto-pen and pre-filled syringe) designed to deal with rheumatoid arthritis and different auto-immune illnesses; IXINITY®, an intravenous recombinant issue IX therapeutic to be used in sufferers 12 years of age or older with Hemophilia B – a hereditary bleeding dysfunction characterised by a deficiency of clotting issue IX within the blood, which is important to regulate bleeding; and Rupall®, an modern prescription allergy treatment with a singular mode of motion.

Ken d’Entremont, Chief Govt Officer
Medexus Prescription drugs Inc.
Tel.: 905-676-0003

Roland Boivin, Chief Monetary Officer
Medexus Prescription drugs Inc.
Tel.: 514-762-2626 ext. 202

Investor Relations (U.S.):
Crescendo Communications, LLC
Tel: +1-212-671-1020
E mail:

Investor Relations (Canada):
Tina Byers
Adelaide Capital
Tel: 905-330-3275

Primary Logo

Products You May Like